| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Peregrine "compares" To Avastin
Posted on 04/16/2007 18:52:14 | Link | Post Comment
by Jon C. Ogg
24/7 Wall St.
Peregrine Pharmaceuticals, Inc. (PPHM-NASDAQ) just issued a press release showing "Peregrine's Selective Anti-VEGF Antibodies Inhibited Tumor Growth By 90% In a Preclinical Cancer Model" AND "Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models."
Keep in mind that these are "advancing toward Linical Trials" and the company is in the developmental stage of making targeted monoclonal antibodies for cancer and hapatitis C. This data is being presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR).
Here is the full press release. Shares are up 9% and this one is only a $1.15 stock after the jump. The 52-week trading range is $0.86 to $1.99; its market cap after the gain is $223 million. PPHM has almost no revenues and has a net book value upon last financial data of about $22.1 million.
Source: 247WallSt.com
___________________
24/7 Wall St.
Peregrine Pharmaceuticals, Inc. (PPHM-NASDAQ) just issued a press release showing "Peregrine's Selective Anti-VEGF Antibodies Inhibited Tumor Growth By 90% In a Preclinical Cancer Model" AND "Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models."
Keep in mind that these are "advancing toward Linical Trials" and the company is in the developmental stage of making targeted monoclonal antibodies for cancer and hapatitis C. This data is being presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR).
Here is the full press release. Shares are up 9% and this one is only a $1.15 stock after the jump. The 52-week trading range is $0.86 to $1.99; its market cap after the gain is $223 million. PPHM has almost no revenues and has a net book value upon last financial data of about $22.1 million.
Source: 247WallSt.com
___________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Trader X
- 360 Digest
- Millionaire Now! by Larry Nusbaum
- Alpha Trends
- Jon Aquino's Mental Garden
- The Boston Condo Blog
Examples
ATM Wallstreet - Sat Oct 04, 2008 10:41PM
When I first started Day Trading I traded anything that [read more]
When I first started Day Trading I traded anything that [read more]
Morpheus Trading - Thu Oct 02, 2008 08:58AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Wed Oct 01, 2008 08:38AM
NOTE: Please click on the charts below to enlarge them [read more]
NOTE: Please click on the charts below to enlarge them [read more]
<< My Home | TheMoneyBlogs Home